Joni Kazantzis was 15 years old when she woke up one morning covered with red, scaly spots that looked a lot like chickenpox. It happened overnight, so her mother thought it may have been an allergic ...

The Food and Drug Administration (FDA) announced that it has accepted the supplemental New Drug Application (sNDA) for roflumilast foam 0.3% in adults and adolescents with scalp and body psoriasis ...

Those are some of the questions dermatologists face when a patient on systemic therapy for psoriasis does not respond fully, when the patient reacts favorably at first but then treatment effectiveness ...

Credit: Getty Images. Roflumilast foam is an investigational topical formulation of a highly potent and selective phosphodiesterase type 4 inhibitor. A phase 3 trial evaluating the efficacy and safety ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients randomized ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. By week 8, patients treated with roflumilast saw higher ...

Adults with moderate to severe psoriasis and overweight or obesity were more likely to achieve complete skin clearance plus ...

Greater body surface area was shown to correlate with an increased risk of psoriatic arthritis development in patients with psoriasis, with obesity and depression also identified as risk factors. Body ...

Psoriasis is a common skin condition that causes raised, red, scaly patches of skin that can feel itchy or painful. But if that inflammation can't be kept in check, it can affect a person's entire ...

Once-daily 0.3% topical roflumilast foam significantly reduced severity in patients with psoriasis of the scalp and body over 8 weeks, with a favorable safety profile. “Use of roflumilast foam was ...